Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;35(1):185-190.
doi: 10.1002/mds.27882. Epub 2019 Nov 11.

Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort

Han-Joon Kim  1 , Sarah Mason  2 , Thomas Foltynie  3 , Sophie Winder-Rhodes  2 , Roger A Barker  2 , Caroline H Williams-Gray  2
Affiliations

Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort

Han-Joon Kim et al. Mov Disord. 2020 Jan.

Abstract

Background: Long-term population-representative data on motor fluctuations and levodopa-induced dyskinesias in Parkinson's disease is lacking.

Methods: The Cambridgeshire Parkinson's Incidence from GP to Neurologist (CamPaIGN) cohort comprises incident PD cases followed for up to 13 years (n = 141). Cumulative incidence of motor fluctuations and levodopa-induced dyskinesias and risk factors were assessed using Kaplan-Meyer and Cox regression analyses.

Results: Cumulative incidence of motor fluctuations and levodopa-induced dyskinesias was 54.3% and 14.5%, respectively, at 5 years and 100% and 55.7%, respectively, at 10 years. Higher baseline UPDRS-total and SNCA rs356219(A) predicted motor fluctuations, whereas higher baseline Mini-mental State Examination and GBA mutations predicted levodopa-induced dyskinesias. Early levodopa use did not predict motor complications. Both early motor fluctuations and levodopa-induced dyskinesias predicted reduced mortality in older patients (age at diagnosis >70 years).

Conclusions: Our data support the hypothesis that motor complications are related to the severity of nigrostriatal pathology rather than early levodopa use and indicate that early motor complications do not necessarily confer a negative prognosis. © 2019 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; levodopa-induced dyskinesias; motor complications; motor fluctuations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan‐Meier plots of survival to onset of motor fluctuations (MFs) and levodopa‐induced dyskinesias (LIDs). Dotted line denotes median time to outcome. [Color figure can be viewed at http://wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Ahlskog JE, Muenter MD. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448–458. - PubMed
    1. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498–2508. - PubMed
    1. Hauser RA, Rascol O, Korczyn AD, et al. Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409–2417. - PubMed
    1. Nicoletti A, Mostile G, Nicoletti G, et al. Clinical phenotype and risk of levodopa‐induced dyskinesia in Parkinson's disease. J Neurol 2016;263:888–894. - PubMed
    1. Olanow CW, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease. Mov Disord 2013;28:1064–1071. - PubMed

Publication types

Substances